SeaBird Exploration Plc
8 January 2021, Limassol, Cyprus
An Extraordinary General Meeting (“EGM”) in SeaBird Exploration Plc (“The Company”) was held on 8 January 2021. All items on the agenda as proposed by the board of directors and set out in the notice of the meeting were adopted.
The EGM approved to reduce The Company’s share premium account and to distribute up to 3,000,000 shares in Green Minerals AS to the shareholders of The Company. Following the approval by the EGM, the Company will file an application to the Registrar in Cyprus for approval of the reduction of the share premium account. When an approval from the Registrar has been granted, the Company will return with an updated ex-date for the distribution of shares in Green Minerals AS.
The minutes of the EGM is attached to this release.
For further queries contact:
Erik von Krogh
CFO
Mob: +47 930 38 075
All statements in this press release other than statements of historical fact are forward-looking statements and are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include SeaBird`s reliance on a cyclical industry and the utilization of the company's vessels. Actual results may differ substantially from those expected or projected in the forward-looking statements.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
